Translational Laboratory

转化实验室

基本信息

批准号：
8340247
负责人：
KEVIN J. CULLEN
金额：
$ 6.93万
依托单位：
UNIVERSITY OF MARYLAND BALTIMORE
依托单位国家：
美国
项目类别：
财政年份：
2011
资助国家：
美国
起止时间：
2011-08-24 至 2016-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8340247
关键词：
Animals Antineoplastic Agents Area Basic Science Biological Biological Assay Biotechnology Cancer Center Cancer Center Support Grant Cancer Model Cell Line Cells Clinical Clinical Trials Correlative Study Data End Point Assay Experimental Designs Future Grant Human Human Resources IACUC Ice In Vitro Instruction Laboratories Laboratory Research Letters Malignant Neoplasms Marrow Maryland Mission Outcome Peripheral Blood Mononuclear Cell Pharmaceutical Preparations Pharmacodynamics Pharmacologic Substance Phase Plasma Play Procedures Process Protocols documentation Research Research Personnel Resources Role Running Screening procedure Services Specificity Specimen Testing Therapeutic Tissues Training Translating Translations Universities Work Writing base bench to bedside drug development human tissue in vivo in vivo Model meetings novel pre-clinical research study tissue processing tool

项目摘要

PROJECT SUMMARY (See instructions): The Translational Laboratory Shared Service (TLSS) supports investigators performing drug development in the preclinical and clinical settings at the University of Maryland Marlene and Stewart Greenebaum Cancer Center (UMGCC). Sen/ices include processing of human clinical trial specimens, developing assays for pharmacodynamic endpoints, assaying novel cancer therapeutics in vitro, and evaluating novel agents aloneor in combination in in vivo cancer models. The TLSS supports both the clinician and basic investigator. For the clinician, the TLSS processes tissue generated from clinical trials, often playing the role of conduit between the clinical trialist and other cores and shared services within UMGCC. Standard operating procedures for processing the material are generated within TLSS and distributed to the necessary personnel involved in administering the clinical trial. In addition, TLSS develops assays to test the functional activity of a novel compound in human tissue from Phase I and Phase l/ll clinical trials. Last, for those clinicians without laboratories of their own, the TLSS provides the opportunity for the clinician to perform basic research or to train residents or interns in laboratory research. A preclinical investigator may choose to utilize TLSS services when the scope of an experiment exceeds the resources available or is outside his or her area of expertise. For example, regarding In vivo work, investigators may prefer to use the TLSS's umbrella animal use protocol (AUP) rather than writing an AUP of their own and processing it through the Institutional Animal Care and Use Committee. Also, TLSS is uniquely set up to screen compounds in multiple cell lines to determine the range, extent, or specificity of efficacy. TLSS personnel meet with both clinicians and basic researchers to discuss experimental designs as well as expected outcomes and appropriate controls. The TLSS is an excellent resource for researchers to use at UMGCC.

项目摘要（参见说明）：转化实验室共享服务 (TLSS) 支持研究人员在马里兰大学马琳和斯图尔特格林鲍姆癌症中心 (UMGCC) 的临床前和临床环境中进行药物开发。服务包括处理人类临床试验样本、开发药效学终点的测定、体外测定新型癌症疗法以及在体内癌症模型中单独或组合评估新型药物。 TLSS 支持临床医生和基础研究者。对于临床医生来说，TLSS 处理临床试验中生成的组织，通常在临床试验人员与 UMGCC 内的其他核心和共享服务之间发挥管道的作用。处理材料的标准操作程序在 TLSS 内生成并分发给必要的人员参与管理临床试验的人员。此外，TLSS 还开发了一些方法来测试 I 期和 I/II 期临床试验中新型化合物在人体组织中的功能活性。最后，对于那些没有自己实验室的临床医生来说，TLSS 为临床医生提供了进行基础研究或培训住院医师或实习生进行实验室研究的机会。临床前研究者可以选择当实验范围超出可用资源或超出其专业领域时，请使用 TLSS 服务。例如，对于体内工作，研究人员可能更喜欢使用 TLSS 的伞式动物使用协议 (AUP)，而不是自己编写 AUP 并通过机构动物护理和使用委员会处理。此外，TLSS 的独特设置可以筛选多种化合物细胞系以确定功效的范围、程度或特异性。 TLSS 人员与临床医生和基础研究人员会面，讨论实验设计以及预期结果和适当的控制。 TLSS 是 UMGCC 的研究人员可以使用的优秀资源。